AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35367170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rivaroxaban (2.5 mg twice daily for 30 days) + DAPT
Number of subjects: 279
Study 35367170 — intervention group
Group type: COMPARATOR
Intervention: Only DAPT
Number of subjects: 279
Study 33135319 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (30-min session of music of their own choice)
Number of subjects: 70
Study 33135319 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia (control group)
Number of subjects: 70
Study 33361487 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 30 min, 3 sessions per week for 4 weeks)
Number of subjects: 26
Study 33361487 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 26
Study 33361487 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 26
Study 618142129 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg synthetic GABA
Number of subjects: 30
Study 618142129 — intervention group
Group type: COMPARATOR
Intervention: 800 mg microcrystalline cellulose (placebo)
Number of subjects: 30
Study 36047565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 263
Study 36047565 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 263
Study 36047565 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 263
Study 34006464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcuticular suture urethroplasty (Group A)
Number of subjects: 260
Study 34006464 — intervention group
Group type: COMPARATOR
Intervention: Interrupted subcuticular suture urethroplasty (Group B)
Number of subjects: 260
Study 32821939 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day remdesivir (n=199)
Number of subjects: 596
Study 32821939 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day remdesivir (n=197)
Number of subjects: 596
Study 32821939 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=200)
Number of subjects: 596
Study 35031521 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus a twice‐daily application‐based mindful meditation program
Number of subjects: 56
Study 35031521 — intervention group
Group type: COMPARATOR
Intervention: Routine care plus educational pamphlets (control arm)
Number of subjects: 56
Study 35031521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (meditation and control)
Number of subjects: 56
Study 36383914 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant lomustine
Number of subjects: 4
Study 34624839 — intervention group
Group type: EXPERIMENTAL
Intervention: activL device
Number of subjects: 283
Study 34624839 — intervention group
Group type: EXPERIMENTAL
Intervention: No preoperative narcotics use
Number of subjects: 283
Study 34624839 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative factors (unrestricted full-time work, working manual labor after index back injury)
Number of subjects: 283
Study 34624839 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, greater VAS-leg pain score, greater ODI score, female sex, working manual labor before back injury
Number of subjects: 283
Study 34624839 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BMI, VAS-back pain score, back pain duration ≥ 1 year, SF-36 physical component summary score, recreational activity
Number of subjects: 283
Study 32532326 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended doxycycline treatment (100 mg twice daily for 1 week before and after oocyte retrieval)
Number of subjects: 305
Study 32532326 — intervention group
Group type: COMPARATOR
Intervention: Salpingectomy (laparoscopic salpingectomy with coagulation of mesosalpinx)
Number of subjects: 305
Study 35042948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (d-amp) 10 or 20 mg
Number of subjects: 23
Study 35042948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (d-amp)
Number of subjects: 23
Study 35042948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 34758698 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching educational videos on the harms of waterpipe tobacco smoking (WTS)
Number of subjects: 208
Study 34758698 — intervention group
Group type: EXPERIMENTAL
Intervention: Video focused on physical harms of WTS
Number of subjects: 208
Study 34758698 — intervention group
Group type: EXPERIMENTAL
Intervention: All four videos (physical harms, myths about WTS, addiction, harms to others)
Number of subjects: 208
Study 34758698 — intervention group
Group type: COMPARATOR
Intervention: Not watching a video
Number of subjects: 208
Study 32603351 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR (blood flow restriction) training (4 sets at 30% 1-RM until failure)
Number of subjects: 21
Study 32603351 — intervention group
Group type: EXPERIMENTAL
Intervention: NoBFR training (4 sets at 30% 1-RM until failure)
Number of subjects: 21
Study 32603351 — intervention group
Group type: COMPARATOR
Intervention: BFR training
Number of subjects: 21
Study 32603351 — intervention group
Group type: COMPARATOR
Intervention: NoBFR training
Number of subjects: 21
Study 35250287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen A (broad spectrum sunscreen with anti-inflammatory agent)
Number of subjects: 59
Study 35250287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen A
Number of subjects: 59
Study 35250287 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen B (regular sunscreen)
Number of subjects: 59
Study 35761117 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Number of subjects: 0
Study 35761117 — intervention group
Group type: COMPARATOR
Intervention: CT+WBBS
Number of subjects: 0
Study 35761117 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 0
Study 33834625 — intervention group
Group type: COMPARATOR
Intervention: Citrus aurantium standardised reference materials (SRMs)
Number of subjects: 12
Study 33834625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐workout supplements
Number of subjects: 12
Study 32484736 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of eating disorder behaviours (EDBs)
Number of subjects: 6034
Study 32484736 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of onset of eating disorder behaviours (EDBs)
Number of subjects: 6034
Study 36001790 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 25
Study 36001790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 34058100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC group)
Number of subjects: 543
Study 34058100 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Exercise (EX group)
Number of subjects: 543
Study 34058100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 543
Study 35700837 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (0.6 mg/day escalating to 3.0 mg/day over 5 weeks)
Number of subjects: 54
Study 35700837 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin (10 mg twice daily for 12 weeks)
Number of subjects: 54
Study 35608694 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with 450-nm blue LED and curcumin photosensitizer
Number of subjects: 30
Study 35608694 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with low-level laser therapy
Number of subjects: 30
Study 35608694 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with nystatin
Number of subjects: 30
Study 36261261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (Bupi group)
Number of subjects: 76
Study 36261261 — intervention group
Group type: COMPARATOR
Intervention: Liposomal bupivacaine plus bupivacaine (LB group)
Number of subjects: 76
Study 33663582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangguixu-san (DS)
Number of subjects: 48
Study 33663582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32683741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-cylinder method
Number of subjects: 50
Study 32683741 — intervention group
Group type: COMPARATOR
Intervention: Single method
Number of subjects: 50
Study 36455242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch Elevation Training (PET)
Number of subjects: 30
Study 36455242 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulation-Resonance Training (ART)
Number of subjects: 30
Study 36455242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PET and ART
Number of subjects: 30
Study 36455242 — intervention group
Group type: COMPARATOR
Intervention: Sham Training
Number of subjects: 30
Study 33560322 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfusion triggered by hemoglobin ≤8; n=342)
Number of subjects: 668
Study 33560322 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfusion triggered by hemoglobin ≤10 g/dL; n=324)
Number of subjects: 668
Study 33560322 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 668
Study 33560322 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 668
Study 32728162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypospadias cases
Number of subjects: 0
Study 32728162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34417649 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto (intervention group)
Number of subjects: 6390
Study 34417649 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 6390
Study 34417649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 6390
Study 34688059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (5 sessions of 60 minutes per week for 8 weeks)
Number of subjects: 330
Study 34688059 — intervention group
Group type: COMPARATOR
Intervention: Control group (health education program)
Number of subjects: 330
Study 33234786 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention‐based U‐Net
Number of subjects: 75
Study 33234786 — intervention group
Group type: COMPARATOR
Intervention: Generic 3‐D U‐Net
Number of subjects: 75
Study 34430896 — intervention group
Group type: EXPERIMENTAL
Intervention: Expandable femoral fixation
Number of subjects: 48
Study 34430896 — intervention group
Group type: COMPARATOR
Intervention: Suspensory femoral fixation
Number of subjects: 48
Study 35833528 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Periodontal Infection Control (GPIC)
Number of subjects: 615
Study 35833528 — intervention group
Group type: COMPARATOR
Intervention: Conventional Non-Surgical Therapy (CNST)
Number of subjects: 615
Study 33843245 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilogy lithotripter
Number of subjects: 100
Study 33843245 — intervention group
Group type: COMPARATOR
Intervention: ShockPulse‐SE lithotripter
Number of subjects: 100
Study 33272623 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg/d of follitropin delta
Number of subjects: 158
Study 33272623 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 μg/d of follitropin delta
Number of subjects: 158
Study 33272623 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 μg/d of follitropin delta
Number of subjects: 158
Study 33272623 — intervention group
Group type: COMPARATOR
Intervention: 150 IU/d of follitropin beta (control)
Number of subjects: 158
Study 33272623 — intervention group
Group type: EXPERIMENTAL
Intervention: follitropin delta
Number of subjects: 158
Study 35172199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified curriculum using Kahoot!
Number of subjects: 73
Study 35172199 — intervention group
Group type: COMPARATOR
Intervention: Nongamified curriculum (control group)
Number of subjects: 73
Study 34330170 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant 20 mg
Number of subjects: 60
Study 34330170 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam 2 mg
Number of subjects: 60
Study 34330170 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 32611863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated water
Number of subjects: 60
Study 32611863 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 60
Study 32611863 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 34470053 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal high definition-transcranial direct current stimulation (HD-tDCS) over dlPFC
Number of subjects: 68
Study 34470053 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal high definition-transcranial direct current stimulation (HD-tDCS) over PPC
Number of subjects: 68
Study 34470053 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 68
Study 34622762 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg or 300 mg every four weeks
Number of subjects: 173
Study 32726475 — intervention group
Group type: EXPERIMENTAL
Intervention: ENACT group visits (n=55), two 2-hour sessions discussing ACP topics and using ACP tools.
Number of subjects: 110
Study 32726475 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=55), received Conversation Starter Kit and Medical Durable Power of Attorney form by mail.
Number of subjects: 110
Study 34607738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand therapy
Number of subjects: 57
Study 34607738 — intervention group
Group type: COMPARATOR
Intervention: Independent exercise (IE)
Number of subjects: 57
Study 32959898 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural management program
Number of subjects: 71
Study 32959898 — intervention group
Group type: COMPARATOR
Intervention: Standard communication approach
Number of subjects: 71
Study 32360042 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished surface (400‐1200‐grit SiC papers)
Number of subjects: 60
Study 32360042 — intervention group
Group type: COMPARATOR
Intervention: Roughened surface (200‐grit SiC papers)
Number of subjects: 60
Study 33966428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaochang Xiaoliu Decoction Granules (TXDG)
Number of subjects: 0
Study 33966428 — intervention group
Group type: COMPARATOR
Intervention: TXDG mimetic agent
Number of subjects: 0
Study 36458325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 10 days (V10)
Number of subjects: 234
Study 36458325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 14 days (V14)
Number of subjects: 234
Study 36458325 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 14 days (E14)
Number of subjects: 234
Study 36458325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily (V10)
Number of subjects: 234
Study 36458325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily (V14)
Number of subjects: 234
Study 36458325 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg (E14)
Number of subjects: 234
Study 34275866 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door HIV self-testing (HIVST)
Number of subjects: 2582
Study 34275866 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 2582
Study 32960847 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab)
Number of subjects: 0
Study 32960847 — intervention group
Group type: COMPARATOR
Intervention: PD-1 inhibitors
Number of subjects: 0
Study 33782985 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS Expert (biodegradable polymer eluting paclitaxel)
Number of subjects: 445
Study 33782985 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS LIM (biodegradable polymer eluting sirolimus)
Number of subjects: 445
Study 33782985 — intervention group
Group type: COMPARATOR
Intervention: Regular drug-eluting stent (rDES)
Number of subjects: 445
Study 33782985 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS Expert
Number of subjects: 445
Study 33782985 — intervention group
Group type: COMPARATOR
Intervention: rDES
Number of subjects: 445
Study 36335048 — intervention group
Group type: EXPERIMENTAL
Intervention: aboBoNT‐A 500U
Number of subjects: 186
Study 36335048 — intervention group
Group type: COMPARATOR
Intervention: aboBoNT‐A 300U
Number of subjects: 186
Study 36335048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 33378989 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of favipiravir and tocilizumab
Number of subjects: 26
Study 33378989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 26
Study 32200506 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Pulse Technology (OPT)
Number of subjects: 62
Study 32200506 — intervention group
Group type: COMPARATOR
Intervention: Intense Regulated Pulsed Light (IRPL)
Number of subjects: 62
Study 34301226 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP (CompuLsive Exercise Activity TheraPy)
Number of subjects: 128
Study 34301226 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 128
Study 36184345 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 265
Study 36184345 — intervention group
Group type: COMPARATOR
Intervention: Consult as usual (CAU)
Number of subjects: 265
Study 34474282 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-randomization NMB
Number of subjects: 548
Study 34474282 — intervention group
Group type: COMPARATOR
Intervention: Not receiving post-randomization NMB
Number of subjects: 548
Study 34474282 — intervention group
Group type: EXPERIMENTAL
Intervention: NMB use
Number of subjects: 548
Study 35894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward span training
Number of subjects: 60
Study 35894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward span training
Number of subjects: 60
Study 35894226 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 60
Study 32619206 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta binaural beat (TBB) auditory stimulus
Number of subjects: 64
Study 32619206 — intervention group
Group type: COMPARATOR
Intervention: Control group (pink sound and carrier tones without TBB)
Number of subjects: 64
Study 32692000 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 treatment in emergency departments
Number of subjects: 1000
Study 32692000 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables
Number of subjects: 1000
Study 32692000 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary test findings
Number of subjects: 1000
Study 36451216 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) for Plasmodium falciparum
Number of subjects: 379
Study 36451216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PPQ) for Plasmodium falciparum
Number of subjects: 379
Study 36451216 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) for Plasmodium vivax
Number of subjects: 379
Study 36451216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PPQ) for Plasmodium vivax
Number of subjects: 379
Study 33952552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 1132
Study 33952552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132
Study 32847494 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education intervention (six-week group-based)
Number of subjects: 150
Study 32847494 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 150
Study 33290336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate (BMAC)
Number of subjects: 12
Study 33290336 — intervention group
Group type: COMPARATOR
Intervention: Control (no enhancement)
Number of subjects: 12
Study 33910468 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 65
Study 33910468 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 65
Study 32979576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-content screening (HCS) strategy
Number of subjects: 104
Study 32979576 — intervention group
Group type: COMPARATOR
Intervention: Classic isolation procedure
Number of subjects: 104
Study 33023276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuun electrolyte tablets (single dose)
Number of subjects: 18
Study 33023276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuun electrolyte tablets (double dose)
Number of subjects: 18
Study 33023276 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 18
Study 35562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-based DASH diet
Number of subjects: 300
Study 35562742 — intervention group
Group type: COMPARATOR
Intervention: Traditional DASH diet
Number of subjects: 300
Study 33469752 — intervention group
Group type: EXPERIMENTAL
Intervention: Training alone
Number of subjects: 58
Study 33469752 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and municipal support (less intensive)
Number of subjects: 58
Study 33469752 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and municipal support (more intensive)
Number of subjects: 58
Study 33469752 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 58
Study 35211253 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide combined with radiotherapy (Group A)
Number of subjects: 120
Study 35211253 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Group B)
Number of subjects: 120
Study 34053798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral crural overlay (LCO)
Number of subjects: 40
Study 34053798 — intervention group
Group type: COMPARATOR
Intervention: Lateral crural transposition
Number of subjects: 40
Study 32788150 — intervention group
Group type: EXPERIMENTAL
Intervention: Active symptom monitoring smartphone app
Number of subjects: 81
Study 32788150 — intervention group
Group type: COMPARATOR
Intervention: Usual management
Number of subjects: 81